India, March 20 -- Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for the treatment of adults with moderately to severely active Crohn's disease or CD, a chronic inflammatory condition of the gastrointestinal tract.
This milestone builds upon the FDA approval of TREMFYA in moderately to severely active ulcerative colitis (UC), one of two main forms of inflammatory bowel disease (IBD), which impacts the lives of nearly three million Americans.
TREMFYA is the first and only approved fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64,...